Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1CNS 1

Conditions

Turcot syndrome 1Medulloblastoma 1Glioma 1Familial ependymoma 1Ependymoma 1Diffuse Intrinsic Pontine Glioma 1Colorectal Neoplasms, Hereditary Nonpolyposis 1Brain Neoplasms 1

Interventions

pembrolizumab 254Cyclophosphamide 244Specimen Handling 196fludarabine 173Magnetic Resonance Spectroscopy 170Biopsy 145Nivolumab 124Carboplatin 99Radiotherapy 92Paclitaxel 90venetoclax 81Cisplatin 80fludarabine phosphate 79Gemcitabine 78Injections 69Ipilimumab 66Dexamethasone 63atezolizumab 58Cetuximab 57Bevacizumab 57Azacitidine 57Radiation 56Fluorouracil 56durvalumab 54Radiosurgery 51Temozolomide 48Oxaliplatin 44Rituximab 43Irinotecan 43Docetaxel 43

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Diffusion Tensor Imaging × 1 year × Clear all
NCT02359565 2026-05-13

Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma

National Cancer Institute (NCI)

Phase 1 Active not recruiting
71 enrolled
CNSGastrointestinal

Familial ependymoma, Turcot syndrome, Diffuse Intrinsic Pontine Glioma, Brain Neoplasms, Colorectal Neoplasms, Hereditary Nonpolyposis, Ependymoma, Glioma, Medulloblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡